Collaboration Agreement Sample Contracts

AutoNDA by SimpleDocs
AND
Collaboration Agreement • January 18th, 2006 • pSivida LTD • Laboratory analytical instruments • Georgia
BETWEEN
Collaboration Agreement • June 5th, 2007 • Transition Therapeutics Inc. • New York
EXHIBIT 10.13 COLLABORATION AGREEMENT
Collaboration Agreement • March 22nd, 2005 • BioNumerik Pharmaceuticals, Inc. • Services-commercial physical & biological research
AMENDED AND RESTATED COLLABORATION AGREEMENT
Collaboration Agreement • August 9th, 2019 • Tg Therapeutics, Inc. • Pharmaceutical preparations • New York

THIS AMENDED AND RESTATED COLLABORATION AGREEMENT (the “Agreement”) is dated as of June 19, 2019 by and between Checkpoint Therapeutics, Inc., a Delaware corporation organized having its place of business at 2 Gansevoort Street, New York, NY 10014 (“CTI”), and TG Therapeutics, Inc. located at 2 Gansevoort Street, New York, NY 10014 (“TGTX”). CTI, on the one hand, and TGTX, on the other hand, shall each be referred to herein as a “Party” or, collectively, as the “Parties.”

Collaboration Agreement between Institute of Grassland and Environmental Research and Ceres, Inc.
Collaboration Agreement • January 25th, 2012 • Ceres, Inc. • Agricultural production-crops • New York

THIS AGREEMENT is made this 1st day of April, 2007 (“Effective Date”), by and between INSTITUTE OF GRASSLAND AND ENVIRONMENTAL RESEARCH (“IGER”), a company limited by guarantee, registered in England No. 473456 and a registered Charity No. 272150, having an office at Plas Gogerddan, Aberystwyth, Ceredigion, SY23 3EB, United Kingdom and CERES, INC. (“CERES”), a Delaware corporation, having an office at 1535 Rancho Conejo Blvd., Thousand Oaks, California 91320, United States of America.

COLLABORATION AGREEMENT between PACIFIC BIOSCIENCES OF CALIFORNIA, INC. and GEN-PROBE INCORPORATED Dated as of June 15, 2010
Collaboration Agreement • November 3rd, 2010 • Gen Probe Inc • Surgical & medical instruments & apparatus • California

THIS COLLABORATION AGREEMENT (the “Agreement”) is entered into between Pacific Biosciences of California, Inc., a Delaware corporation (“PacBio”), having a place of business at 1505 Adams Drive, Menlo Park, California 94025 and Gen-Probe Incorporated, a Delaware corporation (“Gen-Probe”), having a place of business at 10210 Genetic Center Drive, San Diego, California 92121. PacBio and Gen-Probe may each sometimes be referred to herein as a “party” and collectively as the “parties.”

COLLABORATION AGREEMENT
Collaboration Agreement • January 8th, 2014 • Biocept Inc • Services-medical laboratories • California

THIS COLLABORATION AGREEMENT (the “Agreement”) is entered into as of November 2, 2012 (the “Effective Date”) by and between BIOCEPT, INC., a California corporation having an address of 5810 Nancy Ridge Drive, Suite 150, San Diego, CA 92121 (“Biocept”), and LIFE TECHNOLOGIES CORPORATION, a Delaware corporation having an address of 5791 Van Allen Way, Carlsbad, California 92008 (“Life Technologies”).

Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. COLLABORATION AGREEMENT
Collaboration Agreement • September 18th, 2006 • Infinity Pharmaceuticals, Inc. • Pharmaceutical preparations • Massachusetts

THIS COLLABORATION AGREEMENT (the “Agreement”) is entered into as of the 24th day of February, 2006 (the “Effective Date”), by and between Infinity Pharmaceuticals, Inc., a Delaware corporation having an office at 780 Memorial Drive, Cambridge, Massachusetts 02139 (“Infinity”), and Novartis Institutes for BioMedical Research, Inc., a Delaware corporation having an office at 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (“Novartis”).

NOW THEREFORE this Agreement witnesses that the parties mutually covenant and agree as follows: 3 PART 1
Collaboration Agreement • July 3rd, 2000 • Graftech Inc • Electrical industrial apparatus • British Columbia
COLLABORATION AGREEMENT by and between VOYAGER THERAPEUTICS, INC. and GENZYME CORPORATION February 11, 2015
Collaboration Agreement • November 6th, 2015 • Voyager Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts

THIS COLLABORATION AGREEMENT (this “Agreement”), entered into as of February 11, 2015 (the “Effective Date”), is entered into by and between Voyager Therapeutics, Inc., a corporation organized and existing under the laws of Delaware (“Voyager”), and, Genzyme Corporation, a corporation organized and existing under the laws of the Commonwealth of Massachusetts (“Genzyme”).

COLLABORATION AGREEMENT
Collaboration Agreement • January 8th, 2014 • Biocept Inc • Services-medical laboratories • California

THIS COLLABORATION AGREEMENT (the “Agreement”) is entered into as of August 17, 2011 (the “Effective Date”) by and between BIOCEPT, INC., a California corporation having an address of 5810 Nancy Ridge Drive, Suite 150, San Diego, CA 92121 (“Biocept”), and CLARIENT DIAGNOSTIC SERVICES, INC., a Delaware corporation having an address of 31 Columbia, Aliso Viejo, California 92656 (“Clarient”).

COLLABORATION AGREEMENT
Collaboration Agreement • May 11th, 2015 • Ignyta, Inc. • Pharmaceutical preparations • Delaware

This COLLABORATION AGREEMENT (the “Agreement”), effective as of November 3, 2006 (the “Effective Date”), is made by and between Ambit Biosciences Corporation a Delaware corporation, having a principal place of business at 4215 Sorrento Valley Boulevard, San Diego, CA 92121 (“Ambit”), and Cephalon, Inc., a Delaware corporation, having a principal place of business at 41 Moores Road, Frazer, PA 19355 (“Cephalon”).

COLLABORATION AGREEMENT
Collaboration Agreement • March 28th, 2013 • Ambit Biosciences Corp • Pharmaceutical preparations • California

This Collaboration Agreement (the “Agreement”) is entered into as of September 14, 2010 (the “Effective Date”) by and between AMBIT BIOSCIENCES CORPORATION, a Delaware corporation with its principal place of business located at 4215 Sorrento Valley Blvd., San Diego, California 92121 (“Ambit”), and GENOPTIX, INC., a Delaware corporation with its principal place of business located at 1811 Aston Avenue, Carlsbad, California 92008 (“Genoptix”). Ambit and Genoptix are also herein designated individually as “Party” and collectively as “Parties.”

ARTICLE 1 - SCOPE OF COLLABORATION; COLLABORATION ACTIVITIES
Collaboration Agreement • September 24th, 2007 • Healthcare Acquisition Corp • Blank checks • Delaware
Collaboration Agreement
Collaboration Agreement • February 14th, 2020 • Senmiao Technology LTD • Finance services

This Collaboration Agreement (hereinafter referred to as this “Agreement”) is made and entered into by and between the following parties in Haidian District, Beijing. This Agreement may be executed in paper form offline or in electronic form through the Didi Chuxing Online Contracting Platform (website: https://contract.didichuxing.com/, hereinafter referred to as the “Contracting Platform”). The Agreement executed offline in paper form shall become effective upon the completion of the execution by both Parties (hereinafter referred to as the “Effective Date”); and the Agreement executed online in electronic form shall become effective upon the completion of the execution on the Contracting Platform by both Parties (hereinafter referred to as the “Effective Date”) recorded by the third-party online document depository.

Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Triple asterisks denote omissions. COLLABORATION AGREEMENT
Collaboration Agreement • October 4th, 2013 • Macrogenics Inc • Pharmaceutical preparations

*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission.

AMENDMENT NO. 2 TO COLLABORATION AGREEMENT
Collaboration Agreement • February 25th, 2005 • Adolor Corp • Pharmaceutical preparations

THIS AMENDMENT NO. 2 TO COLLABORATION AGREEMENT (this “Amendment No. 2”), dated as of December 22, 2004 (the “Effective Date”), is made by and between ADOLOR CORPORATION, a Delaware corporation and having its principal office at 700 Pennsylvania Drive, Exton, Pennsylvania 19341 (“Adolor”), and GLAXO GROUP LIMITED, a United Kingdom corporation and having its principal office at Glaxo Wellcome House, Berkely Avenue, Greenford, Middlesex, UB6 0NN, United Kingdom (“GSK”). Adolor and GSK are each sometimes referred to individually as a “Party” and together as the “Parties.”

COLLABORATION AGREEMENT by and among Boehringer Ingelheim International GmbH, Evotec OAIAG and Evotec Neurosciences GmbH
Collaboration Agreement • March 12th, 2008 • Evotec AG • Pharmaceutical preparations

Boehringer Ingelheim International GmbH (VAT-ID No: DE 811138149) having offices at Binger Strasse 173, 55216 Ingelheim, Germany (hereinafter referred to as “BOEHRINGER”)

AutoNDA by SimpleDocs
RECEPTOS CONFIDENTIAL COLLABORATION AGREEMENT
Collaboration Agreement • April 16th, 2013 • Receptos, Inc. • Pharmaceutical preparations • New York

This Collaboration Agreement (the “Agreement”) is made as of December 20, 2010 (the “Effective Date”) by and between Receptos, Inc., a Delaware corporation (“Receptos”) located at 10835 Road to the Cure, Suite #205, San Diego, California 92121 and Eli Lilly and Company, an Indiana corporation (“Lilly”) having its principal place of business at Lilly Corporate Center, Indianapolis, Indiana 46285 USA.

COLLABORATION AGREEMENT
Collaboration Agreement • December 3rd, 2014 • Cardax, Inc. • Pharmaceutical preparations • New York

THIS COLLABORATION AGREEMENT (“Agreement”) is made as of this 18th day of August 2014 (the “Effective Date”), by and between Capsugel US, LLC and its Affiliates with an address at 412 Mt. Kemble Ave, Suite 200C, Morristown, NJ 07960 (“CAPSUGEL”) and Cardax, Inc., and its Affiliates, with a corporate address at 2800 Woodlawn Dr., Suite 129, Honolulu, HI 96822 (“CARDAX”). CARDAX and CAPSUGEL are each a “Party” and together constitute the “Parties”

BETWEEN MYISCO SDN BHD
Collaboration Agreement • January 19th, 2024 • TETE Technologies Inc • Services-business services, nec
COLLABORATION AGREEMENT
Collaboration Agreement • April 16th, 2013 • Receptos, Inc. • Pharmaceutical preparations • New York

This Collaboration Agreement (the “Agreement”) is made as of December 5, 2011 (the “Effective Date”) by and between Receptos, Inc. (“Receptos”), a Delaware corporation located at 10835 Road to the Cure, Suite #205, San Diego, California 92121, USA and Ono Pharmaceutical Co., Ltd. (“ONO”), a corporation organized under the laws of Japan, having its principal place of business at 8-2, Kyutaromachi 1-chome, Chuo-ku, Osaka 541-8564, Japan.

COLLABORATION AGREEMENT
Collaboration Agreement • November 23rd, 2009 • Ecology Coatings, Inc. • Wholesale-industrial machinery & equipment • Virginia

The Agreement is by and between Reynolds Innovations Inc. (hereinafter “RII”) and Ecology Coatings Inc. (hereinafter “Supplier”). The effective date of this Agreement is April 1st, 2009.

COLLABORATION AGREEMENT dated June 15, 2010 by and between Abbott International Luxembourg S.à r.l. and Neurocrine Biosciences, Inc.
Collaboration Agreement • May 5th, 2021 • Neurocrine Biosciences Inc • Biological products, (no disgnostic substances)

COLLABORATION AND LICENSE AGREEMENT (the “Agreement”) dated as of June 15, 2010 (“Effective Date”) by and between Abbott International Luxembourg S.à r.l., a corporation organized and existing under the laws of Luxembourg, with offices at 26, Boulevard Royal, L-2449 Luxembourg (“ Abbott ”) and Neurocrine Biosciences, Inc., a corporation organized and existing under the laws of Delaware with offices at 12780 El Camino Real, San Diego, California 92130 (“ Neurocrine ”).

COLLABORATION AGREEMENT by and between SURFACE ONCOLOGY, INC. and NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.
Collaboration Agreement • March 23rd, 2018 • Surface Oncology, Inc. • Biological products, (no disgnostic substances) • New York

THIS COLLABORATION AGREEMENT (this “Agreement”), entered into as of January 9, 2016 (the “Effective Date”), is entered into by and between Surface Oncology, Inc., a corporation organized and existing under the Laws of the State of Delaware (“Surface”), and Novartis Institutes for BioMedical Research, Inc., a corporation organized and existing under the Laws of the State of Delaware (“Novartis”). Surface and Novartis are referred to in this Agreement individually as a “Party” and collectively as the “Parties”.

SECOND AMENDED AND RESTATED COLLABORATION AGREEMENT MONSANTO COMPANY and EVOGENE LTD. October 27, 2013
Collaboration Agreement • November 19th, 2013 • Evogene Ltd. • Agricultural chemicals • New York

This SECOND AMENDED AND RESTATED COLLABORATION AGREEMENT (“Agreement”), dated October 27 2013, by and between Monsanto Company, a Delaware corporation (“Monsanto”), and Evogene Ltd., an Israeli company (“Evogene”), shall be effective as of the 2013 Signing Date.

CONFIDENTIAL PROVISIONS REDACTED COLLABORATION AGREEMENT
Collaboration Agreement • December 4th, 2008 • Facet Biotech Corp • Pharmaceutical preparations • California

THIS COLLABORATION AGREEMENT (the “Agreement”) is entered into as of September 12, 2005 (the “Effective Date”) by and between Protein Design Labs, Inc., a Delaware corporation having its offices at 34801 Campus Drive, Fremont, California 94555 (“PDL”), and Biogen Idec MA Inc., a Massachusetts corporation having offices at 14 Cambridge Center, Cambridge, Massachusetts 02142 (“Biogen Idec”). PDL and Biogen Idec may each be referred to in this Agreement individually as a “Party” and collectively as the “Parties.”

SECOND RESTATED COLLABORATION AGREEMENT
Collaboration Agreement • March 12th, 2010 • Celldex Therapeutics, Inc. • In vitro & in vivo diagnostic substances • Delaware

THIS SECOND RESTATED COLLABORATION AGREEMENT (this “Agreement”), dated as of April 12, 2004, the “Revision Date”, is made between ABGENIX, INC., a Delaware corporation (“ABX”), having a place of business at 7601 Dumbarton Circle, Fremont, California 94555, and CURAGEN CORPORATION, a Delaware corporation (“CuraGen”), having a place of business at 555 Long Wharf Drive, New Haven, Connecticut 06511, with respect to the following facts:

Time is Money Join Law Insider Premium to draft better contracts faster.